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Abstract
Background: Prophylactic cranial irradiation (PCI) has been demonstrated to reduce or delay the
incidence of brain metastases (BM) in locally advanced non-small cell lung carcinoma (LA-NSCLC)
patients with various prognostic groups. With this current cohort we planned to evaluate the
potential usefulness of prophylactic cranial irradiation (PCI) specifically in recursive partitioning
analysis (RPA) Group 1, which is the most favorable group of LA-NSCLC patients.
Methods: Between March 2007 and February 2008, 62 patients in RPA group 1 were treated with
sequential chemoradiotherapy and PCI for stage IIIB NSCLC. The induction chemotherapy
consisted of 3 courses of cisplatin (80 mg/m2) and docetaxel (80 mg/m2); each course was given
every 21 days. Thoracic radiotherapy (TRT) was given at a dose of 60 Gy using 3-D conformal
planning. All patients received a total dose of 30 Gy PCI (2 Gy/fr, 5 days a week), beginning on the
first day of the TRT. Then, all patients received 3 further courses of the same chemotherapy
protocol.
Results: Six (9.7%) patients developed brain metastases during their clinical course. Only one (2%)
patient developed brain metastasis as the site of first treatment failure. Median brain metastasis-
free survival, overall survival, and progression free survival were 16.6, 16.7, and 13.0 months,
respectively. By univariate analysis, rates of BM were significantly higher in patients younger than
60 years of age (p = 0.03). Multivariate analysis showed no significant difference in BM-free survival
according to gender, age, histology, and initial T- and N-stage.
Conclusion: The current finding of almost equal bone metastasis free survival and overall survival
in patients with LA-NSCLC in RPA group 1 suggests a longer survival for patients who receive PCI,
and thereby have a reduced risk of BM.
Background
Brain metastases (BM) are a common complication of
locally advanced non-small cell lung cancer (LA-NSCLC),
especially in patients who undergo radical treatment pro-
tocols. Of these patients, 21% to 54% develop BM during
the course of their disease. [1-3]. and another 15–30%
carry a risk of the first treatment failure occurring in the
brain. [4-7]. Studies have shown that the addition of
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chemotherapy to radiation therapy (RT) reduces extracra-
nial distant metastases. [5]. and improves survival. [8,9].
but does not alter brain relapse rates. [5]. which empha-
sizes the need for treatment directed at BM micrometas-
tases. In selected non-randomized [1,4,10-12]. and
randomized studies. [6,7,13,14]. prophylactic cranial irra-
diation (PCI) has been demonstrated to reduce the inci-
dence or delay the onset of BM in patients with LA-NSCLC
after primary therapy.
Several factors including histology, stage, duration of sur-
vival, performance status, chemotherapy protocol, age at
presentation, and sex have been associated with risk of BM
development. [2,13,15-18]. In earlier studies, recursive
partitioning analysis (RPA) classification was demon-
strated to be a useful tool for predicting survival in
patients with LA-NSCLC. [19,20]. Survival analysis
revealed that RPA classification identified five distinct
subgroups with significantly different median survival
times, ranging from 2.9 mo in Group 5 to 16.2 mo in
Group 1. [20] (Table 1). In addition, longer survival of
patients with LA-NSCLC treated with radiation alone or
radiation plus chemotherapy was associated with an
increased incidence of CNS metastases, according to a
review of data from the Radiation Therapy Oncology
Group (RTOG) studies. [1,2,19]. Based on these different
analyses, it is reasonable to assume that many patients
with LA-NSCLC do not live long enough to develop brain
failure. We hypothesized that studies including patients
with various RPA groups may not reflect the true value of
PCI in specific groups; thus, with the current cohort we
specifically evaluated the role of PCI in RPA Group 1
(Karnofsky performance status ≥ 90 and previously
treated by chemotherapy).
Methods
Patients
This retrospective analysis included 62 patients with a his-
tological diagnosis of LA-NSCLC (stage IIIB) meeting the
following criteria; age older than 18 and younger than 70
years, RPA Group 1 (Karnofsky Performance Status (KPS)
≥ 90, previously treated by cisplatin-based chemother-
apy), no superior sulcus tumor, no progressive disease fol-
lowing induction chemotherapy, no prior history of
thoracic and cranial RT, no more than 10% weight loss in
the last 6 months, and signed written informed consent,
those treated at our institution between March 2007 and
February 2008. Further staging procedures included labo-
ratory investigations, computed tomography of the thorax
and abdomen, bone scintigraphy, pulmonary function
tests, and baseline magnetic resonance imaging of the
brain showing no suspicion for intracranial metastases.
This study was formally approved by the Baskent Univer-
sity's institutional review board before collection of all
patient information. Pretreatment patient and tumor
characteristics are shown in Table 2.
Chest Irradiation
Three-dimensional conformal radiation therapy (3D-
CRT) was used in all patients. The treatment planning for
eligible patients was based on gross tumor volume (GTV),
which was restricted to all primary tumors and abnor-
mally enlarged hilar or mediastinal lymph nodes greater
than 1 cm in diameter seen on CT images or metabolically
active areas on PET-CT. Clinical target volumes (CTVs)
were defined by adding 1-cm margins to GTVs. Planning
target volume-1 (PTV1) was created by adding an addition
1.5 cm margin to CTVs, and PTV2 (boost field) was
defined as the GTVs plus a 1.5-cm margin. Three-dimen-
sional CRT was performed to minimize the volume of
normal lung and surrounding normal tissues irradiated
while providing coverage of PTVs by at least 95% isodose
surfaces; the "100% isodose" (prescription doses) were
defined at each isocenter. Thoracic irradiation was given
through the anteroposterior-posteroanterior (AP-PA) por-
tals with individualized multileaf collimator blocks for
PTV1 up to 46 Gy, followed by off-spinal cord oblique
portals up to 60 Gy (14 Gy boost) for PTV2, in a sequen-
tial manner. All patients received daily treatment five days
a week, using 2 Gy fractions administered using linear
accelerators with 6 MV or 18 MV photon energies (Clinac
DBX-1031, and/or DHX-3323, Varian Medical Systems,
Palo Alto, CA, USA). On the initial day of treatment and
every week throughout the treatment, course field loca-
tion was confirmed by comparing the digitally recon-
structed radiographs and the portal images.
Table 1: Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) groups in patients with locally-advanced 
non-small-cell lung cancer (LA-NSCLC).
RPA Group Definition Median survival (months)
I KPS of > or = 90, who received chemotherapy 16.2
II KPS of > or = 90, who received no CT, but had no PE 11.9
III KPS < 90, younger than 70 years, with non-large cell histology 9.6
IV KPS > or = 90, but with PE, or KPS < 90, younger than 70 years, and with large cell histology, or 
older than 70 years, but without PE
5.6–6.4
V older than 70, with PE 2.9
Abbreviations: KPS: Karnofsky Performance Status; CT: Chemotherapy; PE: Pleural effusion.Journal of Experimental & Clinical Cancer Research 2008, 27:80 http://www.jeccr.com/content/27/1/80
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Prophylactic cranial irradiation
Patients were simulated in a supine position with their
heads fixed with thermoplastic head masks; radio-opaque
markers were placed at the lateral orbital canthi to assist
in blocking the lenses. The target volume consisted of all
the intracranial contents with at least a 1-cm margin
around the bony skull at each margin. The inferior border
at the cervical vertebral bodies was the C1-C2 interspace.
Individually shaped radiation fields with multileaf colli-
mators were used to define the irradiation target volume
and exclude tissues that were not to be irradiated. Patients
were treated on a megavoltage linear accelerator with 6
MV photons. All patients received PCI at 2 Gy per fraction,
5 days per week, for 3 weeks, with a total dose of 30 Gy,
beginning on the first day of the thoracic irradiation.
Treatment was delivered with equally weighted right and
left lateral fields with the dose calculated on the central
ray at mid-separation of the beams.
Chemotherapy
All 62 patients received 3 courses of induction chemother-
apy involving cisplatin (80 mg/m2) and docetaxel (80
mg/m2) every 21 days, prior to RT. After completion of RT,
all patients received 3 further courses of the same chemo-
therapy regimen. Chemotherapy was not permitted dur-
ing the course of RT.
Patient evaluation
Patients were examined by a radiation oncologist once a
week during the RT course. After completion of RT,
patients were followed at bimonthly intervals or more fre-
quently if necessary. Besides the standard work-up for
locoregional and distant metastases, an MRI of the brain
was performed at bimonthly intervals or more frequently
if there was a suspicion of BM during the follow-up
period.
Statistics
Variables analyzed were age at the time of diagnosis, gen-
der, histological type (squamous cell carcinoma versus
adenocarcinoma), and T-status (T1-2 versus 3–4), N-sta-
tus (N0-1 versus 2–3). Univariate analyses were per-
formed first for each variable to compare the BM+ and
BM- groups using a Chi-square test. The primary endpoint
was BM-free survival (BMFS), calculated as the time
between the first day of the PCI and the date of BM diag-
nosis. Similarly, overall survival (OS) was calculated as
the time between the first day of the PCI and the date of
death or last visit. Estimates of 1-year and 18-month sur-
vival were calculated by the Kaplan-Meier method, with
comparisons between subsets performed with two-sided
log-rank tests. All tests were two-tailed, with a p-value <
0.05 considered significant.
Results
At a median follow-up of 16.8 months (range: 7–18.6
months), 41 of the 62 patients with LA-NSCLC were alive
at the time of analysis. Median survival for the entire pop-
ulation was 16.7 months (SE: 0.51; 95% CI: 15.7–17.7
months). As illustrated in Figure 1, the 1-year, and 18-
month estimates of the OS were 86% and 62%, respec-
tively. Six patients (9.7%) developed brain metastases at
some time during the course of follow-up. Only one (2%)
patient developed brain metastasis as the site of first fail-
ure. The median time to the development of brain metas-
tases was 7 months (range, 5–13 months). Brain
metastasis was the only site of recurrence in one of six
patients. Among the other five patients with brain metas-
tasis, local progression, liver metastasis, and adrenal
metastasis developed asynchronously in four, two, and
one patient, respectively. Median BMFS was 16.7 months
(SE:0.51, 95% CI: 15.5–17.7 months). Two of the six
patients with brain metastasis were alive at the time of
analysis. As illustrated in Figure 1, BMFS rates at 1 year
and 18 months were 92% and 90%, respectively.
Sites of extracranial failure included liver in eight (12.9%)
patients, bone in five (8.1%), lung in four (6.5%), adrenal
Table 2: Patient and tumor characteristics.
Characteristic n (%)
Gender
Male 48 (77.4)
Female 14 (22.6)
Age (y)
Median (range) 59.6 (38–69)
< 60 26 (41.9)
≥ 60 36 (58.1)
Histology
Epidermoid 51 (82.3)
Adenocarcinoma 11 (17.7)
T-stage
10  ( 0 )
2 13 (21.0)
3 12 (19.3)
4 37 (59.7)
N-stage
0 4 (6.5)
1 13 (21.0)
2 19 (30.6)
3 26 (41.9)
TN-stage
T4, N0 4 (6.5)
T4, N1 13 (21.0)
T4, N2 18 (29.0)
T4, N3 3 (4.8)
T3, N3 11 (17.7)
T2, N3 13 (21.0)
Response to induction CT
CR 11 (17.7)
PR 28 (45.2)
SD 23 (37.1)
Abbreviations: T: Tumor; N: Node; CT: Chemotherapy; CR: 
Complete response; PR: Partially response; SD: Stable disease.Journal of Experimental & Clinical Cancer Research 2008, 27:80 http://www.jeccr.com/content/27/1/80
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in three (4.8%), and more than one site in two (3.2%). A
total of 23 (37.1%) patients developed locoregional
tumor progression during follow-up. Median progression-
free survival was 13.0 months (SE: 2.1; 95% CI: 8.9–17.0)
months. The estimates of 1-year and 18-month progres-
sion-free survival rates for the entire patient population
were 54% and 37%.
By univariate analysis, brain metastasis was significantly
higher in patients with age < 60 years (p = 0.03). An
exploratory analysis of prognostic parameters using a Cox
proportional hazards model showed no significant differ-
ence in BMFS according to gender, age, histology, and ini-
tial T- and N-stage (p > 0.05 for all; Table 3).
Discussion
Several recent studies have reported excellent median and
two-year survival rates of 15–25 months and 37–66%,
respectively, in patients with LA-NSCLC who receive
multi-modal therapy. [1-5,19-25]. Incorporation of sys-
temic chemotherapy was associated with a significant
reduction in the incidence of extracranial metastases and
longer survival; however this was also associated with
increased rates of overall brain failure (21–54%) and
brain as the first site of relapse (15–30%). [1-7,19,25].
These results emphasize the significance of treatment fail-
ure localized to the brain in patients with prolonged sur-
vival after aggressive treatment for LA-NSCLC. This
finding has prompted the inclusion of PCI in some clini-
cal studies. [1,4,10].
PCI, as administered in our protocol, demonstrated effi-
cacy in reducing the incidence of overall BM and the brain
as the first site of relapse (9.7% and 2%, respectively). This
is in accordance with the results of earlier randomized and
non-randomized studies of combined therapies
[1,4,6,7,10-14]. summarized in Table 4. To our knowl-
edge, the current study is the first attempt to specifically
address the role of PCI in patients with LA-NSCLC in RPA
Group 1. Despite the non-randomized nature and rela-
tively short follow-up interval of our study, the BMFS and
OS were almost equal, which suggests a longer survival for
patients with LA-NSCLC who have a reduced BM risk
from PCI protocols such as the one used here. In general,
except for the study published by Pöttgen et al. [14]. in
which only patients with stage IIIA NSCLC were studied,
most studies included patients with disease in various
stages and different histology, including adenosquamous
and large cell tumors. In contrast, the current cohort
included only patients with unresectable stage IIIB disease
with epidermoid or adenocarcinoma histology.
A recent retrospective review of the Southwest Oncology
Group (SWOG) database reported by Gaspar et al.[23].
included 422 patients with stage IIIA/IIIB: 268 (64%)
experienced disease progression; 54 (20%) had progres-
sion in the brain only and 17 (6.5%) in the brain and
other sites simultaneously. Time from treatment to dis-
ease progression in the brain in 71 patients was as follows:
during treatment, 16 relapses (22.5%); 0 to 16 weeks after
treatment, 17 relapses (24%); 16 weeks to 6 months after
treatment, 10 relapses (14%); 6 to 12 months after treat-
ment, 16 relapses (22.5%), and more than 12 months
after treatment, 12 relapses (17%). Thus, 83% of all brain
relapses manifest in the first 12 months after treatment.
Similarly, the median time to the development of brain
metastases was 7 months (range, 5–13 months) in our
study. Based on these results, although longer follow up is
needed, we reasonably estimate that most of the brain
relapses in our current cohort presented during the fol-
low-up period, and potentially only a limited number of
patients will subsequently be further affected; also, the
majority of additional deaths will be associated with local
progression and/or extracranial metastases, rather than
brain failures.
In previously reported PCI studies, the tested total radia-
tion dose and dose per fraction have been tested in previ-
ous studies and ranged from 20 Gy to 36 Gy and 2 Gy to
4 Gy, respectively. [1,4,6,7,10-14]. However, radiation
regimens for PCI that have positively influenced patterns
of CNS failures have included total doses of 30–36 Gy and
fractional doses of 2–3 Gy. [1,4,6,10,14]. For the current
Survival data of patients with locally advanced non-small cell  lung cancer in recursive partitioning analysis group 1 treated  with PCI Figure 1
Survival data of patients with locally advanced non-
small cell lung cancer in recursive partitioning analy-
sis group 1 treated with PCI. BMFS = Brain-metastasis 
free survival, OS = Overall survival, PFS = Progression free 
survival.Journal of Experimental & Clinical Cancer Research 2008, 27:80 http://www.jeccr.com/content/27/1/80
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study, we chose a smaller fractional dose of 2 Gy and a
total dose of 30 Gy to minimize late tissue toxicity, as pre-
ferred in PCI protocols in small cell lung cancer (SCLC).
In a previous study, Stuschke et al. [10]. demonstrated
that this regimen effectively reduced BM from 54% to
13%, with no differences in neuropsychologic testing in
PCI versus non-PCI patients at 4 years. Furthermore, this
75% reduction in the rate of BM is thought to lead to an
8% improvement in OS. [31]. Enlightened with the
present evidence, it is reasonable to expect longer survival
in patients with radically treated LA-NSCLC who recieve
PCI. However, to achieve more firm conclusions, these
estimates regarding the toxicity of PCI and its potential
impact on survival need to be confirmed with larger rand-
omized studies. One such study is the RTOG 0214 trial,
which is a large-scale randomized phase III trial compar-
ing PCI (2 Gy/fraction, totally 30 Gy in three weeks) ver-
sus observation in patients with LA-NSCLC following the
completion of definitive locoregional/systemic therapy. It
is aimed at evaluating whether or not PCI improves sur-
vival by safely decreasing the incidence of CNS metas-
tases. The study was recently closed to accrual and the
patients will be followed for two years in concert with the
primary end-point.
Several factors have been associated with an increased risk
of BM in both stage IIIA and IIIB NSCLC after combina-
tion therapies, including histology (epidermoid vs. non-
epidermoid), gender (female vs. male), age at presenta-
tion (younger vs. older than 50 years), nodal status (pN0
vs. residual nodal disease), performance score (KPS ≥ 70
vs. < 70), duration of survival (long vs. short), and chem-
otherapy protocol (taxane-platinum combination vs.
other platinum-based combinations). [2,15-17,21,24]. In
our cohort, it was not possible to test the predictive role of
chemotherapy, large cell and adenosquamous histologies,
and performance score due to the design of the treatment
protocol, which was limited to patients classified by RPA
groups. However, among the factors that could be ana-
lyzed, only age younger than 60 years was associated with
higher risk of BM incidence following PCI. Additionally,
there was a trend towards a higher risk of BM in patients
with N2-3 stage compared to N0-1, but this difference did
not reach statistical significance (p = 0.07), which may be
due to either the small size of the study population and/
or the short duration of the median follow-up interval.
Despite of the inherent disadvantages, these findings
appear to strongly well correlate with prior reports.
Grouping of patients according to RPA is an established
method for prediction of survival in patients with LA-
NSCLC. The role of RPA classification in predicting BM
development in patients with NSCLC was studied by
Komaki et al. [19]. by reviewing the data from four previ-
ously reported RTOG studies. Analysis showed that
Table 3: Multivariate analyses of predictive factors for brain 
metastases following prophylactic cranial irradiation in patients 
with locally advanced non-small cell lung cancer in recursive 
partitioning analysis group 1.
Variable Estimate (mo) SE 95% CI p-value
Gender (female) 15.7 0.56 14.6–16.8 0.28
Age (< 60) 15.0 0.62 13.8–16.2 0.15
Histology (epidermoid) 16.6 0.58 15.4–17.7 0.16
T-stage (3–4) 16.9 0.63 15.6–18.4 0.92
N-stage (2–3) 16.2 0.65 15.0–17.5 0.07
Abbreviations: T: Tumor; N: Node
Table 4: Studies of prophylactic cranial irradiation for patients with locally advanced non-small cell lung cancer in recursive 
partitioning analysis group 1.
Reference N patients Histology Primary Tx Dose of PCI BM PCI- (%) BM PCI+ (%) P-value
Albain et al.1 126 All NSCLC Trimodality 36 Gy (2 Gy/fr) 16 8 0.36
Strauss et al.4 54 Non-squamous Trimodality 30 Gy (2 Gy/fr) 12 0 0.32
Skarin et al.12 41 All NSCLC Trimodality NS 27 14
Rusch et al.11 75 NS Ctx+TRT 36 Gy (2 Gy/fr)
30 Gy (3 Gy/fr)
-0 -
Stuschke et al.10 75 All NSCLC Trimodality 30 Gy (2 Gy/fr) 54 13 0.0004
Cox et al.5 281 All NSCLC TRT 20 Gy (2 Gy/fr) 13 6 0.038
Unsawasdi.7 97 All NSCLC Trimodality Ctx+TRT 30 Gy (3 Gy/fr) 27 4 0.002
Russell et al.6 187 Non-squamous TRT 30 Gy (3 Gy/fr) 19 9 0.06
Mira et al.32 111 All NSCLC Ctx + TRT 30 Gy (2 Gy/fr)
37.5 Gy (2.5Gy/fr)
11 0 0.0001
Pöttgen et al.14 112 All NSCLC (Stage IIIA) Trimodality 30 Gy (2 Gy/fr) 27.2 9.1 0.02
0.04
Yavuz et al.* 62 Squamous and adeno ca 
(Stage IIIB)
Ctx + TRT 30 Gy (2 Gy/fr) - 9.7 -
(*) Current study.
Abbreviations: Tx = treatment; NSCLC = non-small cell lung cancer, Ctx = chemotherapy, TRT = thoracic radiotherapy; PCI = prophylactic cranial 
irradiation, BM = brain metastasis.Journal of Experimental & Clinical Cancer Research 2008, 27:80 http://www.jeccr.com/content/27/1/80
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patients included in RPA Groups 1 and 2 with the longest
survival had the highest incidence of brain relapses (18%
vs. 9%, p = 0.0004). To our knowledge, none of the previ-
ously reported PCI trials specifically studied a certain RPA
group, and may have included patients belonging to dif-
ferent RPA groups. This raises the suspicion whether the
BMFS might be underestimated by short OS due to deaths
caused by extracranial metastases. Although our median
follow-up was relatively short, the current finding of
almost equal BMFS and OS (16.6 vs. 16.7, respectively) in
RPA Group 1 patients lends further support to the expec-
tation of a longer survival for patients with LA-NSCLC
with reduced risk of BM. We consider that our median sur-
vival data of 16.7 month is similar to RTOG studies which
resulted of 16.2 months for RPA group 1 patients, [20].
and is at least similar to most of the recent chemoradio-
therapy studies published for LA-NSCLC.[25].
One important limitation of our current study is the
absence of the comparative neurocognitive assessments in
pre- and post-PCI periods. In previous retrospective stud-
ies, controversial findings have been reported. [27-31]. In
the meta-analysis of PCI in SCLC, [26]. two trials have
evaluated the effect of PCI on neurocognitive functions.
[27,28]. Arriagada et al.[32]. reported no significant dif-
ferences in neurocognitive function between patients
receiving PCI (24 Gy in 8 fractions) and those in the
observation group. Gregor et al. [31]. randomized
patients to PCI or no PCI. They reported that there was an
impairment of cognitive function and QOL before PCI,
and further impairment at 6 and 12 months in both
groups. No additional impairment was associated with
PCI. None of other randomized trials using PCI, except for
the recent German trial, [14]. collected detailed prospec-
tive data on the long-term effects of PCI on neurocogni-
tive function in patients with NSCLC. An important
limitation of the German trial was the absence of baseline
neurocognitive testing. Nevertheless, no significant differ-
ences were detected in the patient cohort receiving PCI in
comparison with those without PCI despite a detailed
neurocognitive investigation in long-term survivors, more
than 4 years after treatment. Based on the current evidence
from SCLC and NSCLC studies, it is reasonable to assume
that PCI regimens consisting of 20–30 Gy given in 2–3 Gy
per fractions, as used in the current cohort, will produce
little toxicity on brain tissue for the first 1 to 2 years after
PCI. However, further studies with longer follow-up and
sequential pre- and post-PCI evaluations are needed to
fully assess late toxicity of PCI on brain tissue. One hopes
that the recent RTOG 0214 protocol will resolve many
unanswered issues, including the possible changes in neu-
rocognitive function following PCI.
Conclusion
PCI as administered in our protocol demonstrated effi-
cacy in reducing the overall incidence of BM and the rate
at which the brain is the first site of relapse; our findings
also suggest a longer survival for selected patients with LA-
NSCLC. We believe that it is necessary to research the role
of PCI in RPA group 1 patients with LA-NSCLC in rand-
omized clinical trials with larger patient populations; such
studies may provide further data that may help select
patients who are most likely to benefit from PCI.
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